Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.60 EUR
136.88 M EUR
763.75 M EUR
18.47 M
About Laboratorios Farmaceuticos Rovi, S.A.
Sector
Industry
CEO
Juan López-Belmonte Encina
Website
Headquarters
Madrid
Founded
1946
ISIN
ES0157261019
FIGI
BBG000RL1J37
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Laboratorios Farmaceuticos Rovi, S.A. stocks are traded under the ticker 41L.
We've gathered analysts' opinions on Laboratorios Farmaceuticos Rovi, S.A. future price: according to them, 41L price has a max estimate of 92.00 EUR and a min estimate of 65.30 EUR. Watch 41L chart and read a more detailed Laboratorios Farmaceuticos Rovi, S.A. stock forecast: see what analysts think of Laboratorios Farmaceuticos Rovi, S.A. and suggest that you do with its stocks.
Yes, you can track Laboratorios Farmaceuticos Rovi, S.A. financials in yearly and quarterly reports right on TradingView.
Laboratorios Farmaceuticos Rovi, S.A. is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
41L net income for the last quarter is 21.64 M EUR, while the quarter before that showed 18.10 M EUR of net income which accounts for 19.52% change. Track more Laboratorios Farmaceuticos Rovi, S.A. financial stats to get the full picture.
Yes, 41L dividends are paid annually. The last dividend per share was 0.76 EUR. As of today, Dividend Yield (TTM)% is 1.34%. Tracking Laboratorios Farmaceuticos Rovi, S.A. dividends might help you take more informed decisions.
Laboratorios Farmaceuticos Rovi, S.A. dividend yield was 1.20% in 2024, and payout ratio reached 28.30%. The year before the numbers were 1.49% and 27.20% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 1, 2025, the company has 2.2 K employees. See our rating of the largest employees — is Laboratorios Farmaceuticos Rovi, S.A. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Laboratorios Farmaceuticos Rovi, S.A. EBITDA is 201.98 M EUR, and current EBITDA margin is 27.07%. See more stats in Laboratorios Farmaceuticos Rovi, S.A. financial statements.
Like other stocks, 41L shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Laboratorios Farmaceuticos Rovi, S.A. stock right from TradingView charts — choose your broker and connect to your account.